Hemolytic Uremic Syndrome (HUS) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

[Translated article] Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy
CONCLUSIONS: The present study reports supratherapeutic concentrations of eculizumab in patients with aHUS, and defines higher concentrations than those described in the data sheet to achieve blockade, thus encouraging the personalization of treatment with eculizumab.PMID:38057242 | DOI:10.1016/j.farma.2023.09.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - December 6, 2023 Category: Drugs & Pharmacology Authors: Alba Pau Parra Natalia Ramos Janire Perurena-Prieto Silvia Manrique-Rodr íguez Monica Climente Laura Garc ía Quintanilla Ángel Escolano Marta Miarons grupo PK-ECU-ORPHAR Source Type: research

A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy
Antimicrob Agents Chemother. 2023 Dec 4:e0059823. doi: 10.1128/aac.00598-23. Online ahead of print.ABSTRACTShiga toxin-producing Escherichia coli infections are difficult to treat due to the risk of antibiotic-induced stress upregulating the production of toxins, medical treatment is consequently limited to supportive care to prevent the development of hemolytic uremic syndrome (HUS). Here, we introduce a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting Stx2a, the most common Shiga toxin subtype identified from outbreaks. We demonstrate that Hu-mAb 2-5 has low immunogenicity in healthy adu...
Source: Antimicrobial Agents and Chemotherapy - December 4, 2023 Category: Microbiology Authors: Marina E Kirkland Stephanie Patfield Anna C Hughes Bradley Hernlem Xiaohua He Source Type: research

Clinical Evaluation and Management of Thrombotic Microangiopathy
Thrombotic microangiopathy (TMA) refers to a diverse group of diseases that share clinical and histopathologic features. TMA is clinically characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and organ injury that stems from endothelial damage and vascular occlusion. There are several disease states with distinct pathophysiological mechanisms that manifest as TMA. These conditions are associated with significant morbidity and mortality and require urgent recognition and treatment. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are traditionally considered to be primary forms ...
Source: Arthritis and Rheumatology - December 1, 2023 Category: Rheumatology Authors: Joshua Leisring, Sergey V. Brodsky, Samir V. Parikh Tags: Review Source Type: research

Diacylglycerol kinase- ε is S-palmitoylated on cysteine in the cytoplasmic end of its N-terminal transmembrane fragment
J Lipid Res. 2023 Nov 24:100480. doi: 10.1016/j.jlr.2023.100480. Online ahead of print.ABSTRACTDiacylglycerol kinase-ε (DGKε) catalyzes phosphorylation of diacylglycerol to phosphatidic acid with a unique specificity toward 1-stearoyl-2-arachidonoyl-sn-glycerol which is a backbone of phosphatidylinositol (PI). Owing to this specificity, DGKε is involved in the PI cycle maintaining the cellular level of phosphorylated PI derivatives of signaling activity, and was also found crucial for lipid metabolism. DGKε dysfunction is linked with the development of atypical hemolytic uremic syndrome and possibly other human disease...
Source: Cell Research - November 26, 2023 Category: Cytology Authors: Gabriela Traczyk Aneta Hromada-Judycka Anna Świątkowska Julia Wi śniewska Anna Ciesielska Katarzyna Kwiatkowska Source Type: research

Thrombotic microangiopathic anemia after cardiac surgery
Thrombotic microangiopathies (TMA) are characterized by intravascular platelet activation, hemolysis, and microvascular thrombosis causing multi-organ dysfunction. Precipitants include genetic predispositions, acquired immune dysregulation, infection, trauma, medications, organ transplantation, and surgery. TMA's include thrombotic thrombocytopenic purpura (TTP), typical (diarrhea associated) hemolytic uremic syndrome (HUS), atypical (complement mediated) HUS (aHUS), and TMA from secondary causes. (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 25, 2023 Category: Anesthesiology Authors: Craig A Sweeney, Mohammed Quader, Christin Kim Tags: Case Report Source Type: research

Renin and renin blockade have no role in complement activity
Renin, an aspartate protease, regulates the renin-angiotensin system by cleaving its only known substrate angiotensinogen to angiotensin. Recent studies have suggested that renin may also cleave complement component C3 to activate complement or contribute to its dysregulation. Typically, C3 is cleaved by C3 convertase, a serine protease that uses the hydroxyl group of a serine residue as a nucleophile. Here, we provide seven lines of evidence to show that renin does not cleave C3. First, there is no association between renin plasma levels and C3 levels in patients with C3 Glomerulopathies (C3G) and atypical Hemolytic Uremi...
Source: Kidney International - November 24, 2023 Category: Urology & Nephrology Authors: Yuzhou Zhang, Bertha Martin, M. Ashley Spies, Sarah M. Roberts, Joel Nott, Renee X. Goodfellow, Angela FM. Nelson, Samantha J. Blain, Elena Redondo, Carla M. Nester, Richard JH. Smith Tags: basic research Source Type: research

A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience
CONCLUSIONS: Optimizing use of current therapies, as well as identifying and advancing novel therapeutic modalities such as eculizumab, are vital for the improvement of AMR prevention and treatment in LTRs to extend long-term allograft function and survival.PMID:37994573 | DOI:10.1177/10600280231213112 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - November 23, 2023 Category: Drugs & Pharmacology Authors: Hanna L Kleiboeker Alyson Prom Krista Paplaczyk Catherine N Myers Source Type: research

Kidney outcomes in Shiga toxin-associated hemolytic uremic syndrome in childhood: A retrospective single-center study from 1999 to 2017: Kidney outcomes in typical hemolytic uremic syndrome in childhood
CONCLUSION: Adverse kidney outcomes may appear many years after an episode of STECHUS despite an apparent quiescent period. Regular long-term monitoring is required. The challenge is to reduce the proportion of patients lost to follow-up with potentially severe adverse kidney outcomes and no evaluation or treatment.PMID:37989658 | DOI:10.1016/j.arcped.2023.09.016 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - November 21, 2023 Category: Pediatrics Authors: Astrid Viennet Jean-Baptiste Pretalli Rachel Vieux Fran çois Nobili Source Type: research